Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDEAVOR: Carfilzomib vs Bortezomib in Relapsed Multiple Myeloma
NCT01568866Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2012
- Primary completion
- Nov 2014
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 27
01
Overview
A Phase 3 trial of carfilzomib in multiple myeloma (MM), sponsored by Amgen. Started Jun 2012; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01568866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01568866.